Home > Healthcare > Medical Devices > Diagnostic Devices > Premature Rupture of Membranes (PROM) Testing Market

Premature Rupture of Membranes (PROM) Testing Market Trends

Report ID: GMI5895
Published Date: May 2023
Report Format: PDF

Download Free Sample

Premature Rupture of Membranes Testing Market Trends

The rising development of new and improved diagnostic tests will accelerate the PROM testing market. Advancements in diagnostic technologies and the introduction of novel testing methods have the potential to enhance the accuracy, efficiency, and accessibility of PROM testing, thereby improving patient outcomes and driving market growth. The development of enhanced PROM testing for quick and reliable PROM identification has been continuously occurring. This includes the advancement of biomarkers such as insulin-like growth factor-binding protein-1 (IGFBP-1) and placental alpha-microglobulin-1 (PAMG-1). Moreover, a surge in the prevalence of diabetes and cardiovascular diseases doubles a woman's future risk of premature rupture of membranes (PROM). This has resulted in increasing demand for PROM testing and is anticipated to drive market expansion in the future years.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Premature Rupture of Membranes Testing Market was valued at over USD 3 billion in 2022 and is projected to reach more than USD 5 billion by 2032 attributed to the increasing awareness about PROM-related complications and advancements in diagnostic technologies.

The nitrazine test segment is estimated to grow at 5.7% CAGR over 2023-2032 owing to ongoing technological advancements and integration of digital solutions in nitrazine tests to enhance accuracy, ease of use, and interpretation.

The U.S. premature rupture of membranes (PROM) testing market amassed USD 1 billion in 2022 and is anticipated to grow at a robust CAGR through 2032 driven by the high prevalence of preterm births across the nation.

Abbott Laboratories, QIAGEN, Hologic Inc., Medix Biochemica, Biosynex, Clinical Innovations LLC, Sera Prognostics Inc., The Cooper Companies Inc., NX Prenatal Inc., and IQ Products are some of the leading firms in the global premature rupture of membranes (PROM) testing industry.